Medindia LOGIN REGISTER
Medindia
Advertisement

Bradmer announces Dr. Phil Gold to join Board of Directors

Thursday, August 16, 2007 General News
Advertisement
TORONTO, Aug. 15 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., abiopharmaceutical company dedicated to the development and commercializationof cancer therapies, today announced that Phil Gold, C.C., O.Q., M.D., Ph.D.,has agreed to join the Company's Board of Directors effective immediately. Dr.Gold is a pioneer in the study of oncology and physiology with over 40 yearsof experience in clinical and academic settings. His early research led to thediscovery and definition of the Carcinoembryonic Antigen (CEA), the blood testmost frequently used in the diagnosis and management of patients with cancer.
Advertisement

"Dr. Gold's extensive experience in the study and management of cancerwill be of great benefit to our Board of Directors and the senior managementteam at Bradmer," said Mark C. Rogers, M.D., Executive Chairman of Bradmer."As one of the most prominent clinical investigators in Montreal, Dr. Gold hasdemonstrated a commitment, over the course of his career, to help patientsthrough direct patient care as well as working with the pharmaceuticalindustry in developing innovative new therapies. The addition of Dr. Gold isan example of Bradmer's ability, based on our novel Neuradiab therapy, toattract thought leaders in the oncology space."
Advertisement

Dr. Gold is currently the Executive Director of the Clinical ResearchCentre of the McGill University Health Centre. He has also served as Chairmanof the Department of Medicine at McGill and Physician-in-Chief at the MontrealGeneral Hospital. Dr. Gold has been elected to numerous professionalorganizations including the American Society for Clinical Investigation, theAssociation of American Physicians, and Mastership in the American College ofPhysicians. He has been the recipient of a number of prestigious awardsincluding his appointment as a Companion of the Order of Canada and the RobertTaylor Gold Medal from the National Cancer Institute of Canada. Dr. Gold is agraduate of McGill University where he completed his B.Sc. and M.Sc. inphysiology and where he later completed his MDCM and Ph.D. In 2006, the PhilGold Chair in Medicine was inaugurated at McGill University. Dr. Gold will bereplacing Mr. Doug Janzen, President and Chief Business Officer of CardiomePharma Corp. (NASDAQ: CRME, TSX: COM) on the Board of Bradmer.

About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on thedevelopment and commercialization of new and innovative cancer therapies.Bradmer's lead clinical candidate, Neuradiab, was developed at Duke UniversityMedical Center as a proprietary therapy for a particularly aggressive form ofbrain cancer, glioblastoma multiforme. To date, over US$60 million in grantsand related support has driven research and development of the licensedtreatment, which has been delivered to over 200 patients with promisingresults and has completed Phase II clinical trials at Duke University. Bradmeris currently in the process of organizing a pivotal multi-center clinicaltrial of the licensed treatment. Neuradiab has been granted Orphan Drug Statusby both the U.S. Food and Drug Administration and the European MedicinesAgency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registeredunder the Securities Act of 1933, as amended (the "Securities Act") or anystate regulatory agency in the United States. The resale or transfer by a U.S.investor of such common shares of Bradmer Pharmaceuticals Inc. is subject tothe requirements of Rule 904 of Regulation S of the Securities Act or suchother applicable exemption thereunder, and other applicable state securitieslaws.

Except for historical information, this press release may containforward-looking statements, which reflect the Company's current expectationregarding future events. These forward-looking statements involve risk anduncertainties, which may cause but are not limited to,
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close